Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Teh BW et al. Br J Haematol. 2015 Jun 24. doi: 10.1111/bjh.13532. [Epub ahead of print]. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Undas A et al. Blood Coagul Fibrinolysis. 2015 Jun 11. [Epub…
The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/ Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience. Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12.…
Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). Zacchino M et al. Eur Radiol. 2015 May 20. [Epub ahead of print]. Global hypomethylation in myeloma is associated with poor prognosis. Sive JI et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13506. [Epub ahead of print]. Circulating plasma cells in newly diagnosed symptomatic multiple…
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Cibeira MT et al. Br J Haematol. 2015 May 14. doi: 10.1111/bjh.13500. [Epub ahead of print]. Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late? Ramirez GA et al. Intern Med. 2015;54(9):1119-23. doi: 10.2169/internalmedicine.54.3668. Epub 2015 May 1. Abnormal FISH…
A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Benson DM Jr et al. Clin Cancer Res. 2015 May 21. pii: clincanres.0304.2015. [Epub ahead of print]. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Noonan KA et al. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.…
Lenalidomide augments actin remodelling and lowers NK cell activation thresholds. Lagrue K et al. Blood. 2015 May 22. pii: blood-2015-01-625004. [Epub ahead of print]. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in Multiple Myeloma. Yousef S et al. Hum Vaccin Immunother. 2015 May 22:0. [Epub ahead of print]. MicroC3: an ex vivo…
Comparison of Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Single Level Vertebral Compression Fractures: A Meta-analysis of the Literature. Wang H et al. Pain Physician. 2015 May-Jun;18(3):209-22. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Diel IJ et al. Eur J Cancer. 2015 May 11. pii: S0959-8049(15)00373-1. doi: 10.1016/j.ejca.2015.04.017.…
Multiple myeloma: new uses for available agents, excitement for the future. Anderson KC. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):694-6. Expanding role of lenalidomide in hematologic malignancies. Ghosh N et al. Cancer Manag Res. 2015 May 2;7:105-19. doi: 10.2147/CMAR.S81310. eCollection 2015. A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. Sultan S et al. Gulf J Oncolog. 2015 May;1(18):28-31. Mapping Functions in…
Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma. Dogan B et al. Ther Clin Risk Manag. 2015 Apr 30;11:683-9. doi: 10.2147/TCRM.S79232. eCollection 2015. Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation. Apewokin S et al, Transpl Infect Dis. 2015 May 19. doi: 10.1111/tid.12403. [Epub ahead of…
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch W et al. J Cancer Res Clin Oncol. 2015 May 15. [Epub ahead of print]. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Wildes TM et al. Bone Marrow Transplant. 2015 May 11. doi: 10.1038/bmt.2015.106. [Epub…